Cassandra Aikman, MPH
Articles
December 12th 2023
Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes
David T. Liss, PhD Manisha Cherupally, MS Matthew J. O’Brien, MD, MSc Raymond H. Kang, MA Cassandra Aikman, MPH Amisha Wallia, MD, MS Andrew J. Cooper, MSc Eleena Koep, MS Emily D. Parker, PhD, MPH Ronald T. Ackermann, MD, MPH
Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: December 21st 2015 | Updated: January 18th 2025
Patient-Initiated E-mails to Providers: Associations With Out-of-Pocket Visit Costs, and Impact on Care-Seeking and Health
